Imakrebin

Imatinib, the active ingredient in Imakrebin, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of specific cancers that involve BCR‑ABL, c‑KIT, or PDGFR driven pathways, most notably chronic myeloid leukemia and gastrointestinal stromal tumors, and is prescribed by oncologists for adult patients.

GNH USA supplies Imakrebin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imakrebin (imatinib) targets malignant cells driven by specific tyrosine‑kinase pathways and is used in the following clinical settings:

- Chronic myeloid leukemia (CML): provides disease control by inhibiting BCR‑ABL‑positive leukemic cells. - Gastrointestinal stromal tumor (GIST): induces tumor shrinkage through c‑KIT inhibition. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): offers targeted suppression of BCR‑ABL activity in lymphoid blasts.

Imakrebin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of extremities, especially ankles. - Fatigue: persistent tiredness. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Imakrebin, clinicians should observe several safety measures.

- Blood Count Monitoring: perform regular CBC to detect neutropenia. - Liver Function Assessment: check hepatic enzymes before and during therapy. - Cardiac Evaluation: assess baseline cardiac status in patients with pre‑existing heart disease. - Pregnancy Consideration: avoid use unless benefits outweigh potential fetal risks. - Hypersensitivity Warning: discontinue if severe allergic reaction occurs. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Imakrebin interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic exposure. - Antacids containing aluminium or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Diuretics (e.g., furosemide): increased risk of electrolyte disturbances. - Other CYP3A4 substrates (e.g., midazolam): may require dose adjustment of the co‑administered drug.